In addition to their key roles in cellular survival, death, proliferation and metabolism, the Foxo subfamily of forkhead (Fox) transcription factors play critical roles in the homeostasis of immune-relevant cells, including T cells, B cells, neutrophils and other non-lymphoid lineages that modulate inflammation in disease states such as inflammatory arthritis and systemic lupus erythematosus. This review summarizes such current and expanding knowledge of the Foxo family members in immunity, and their potential as therapeutic targets in inflammatory disease.
Structurally and functionally, Foxo proteins-which include Foxo1 (Fkhr), Foxo3a (Fkhrl1), Foxo4 (Afx) and Foxo6 and are all mammalian homologues of the Caenorhabditis elegans longevity and dauer arrest gene DAF-16-remain some of the most well-understood forkhead (Fox) family members, as illustrated by the other reviews in this journal (reviewed in Peng, 2007) . The post-translational regulation of their activities have been exquisitely elucidated; most detailed is the kinasemediated pathway of functional inactivation in response to growth factors, which involves 14-3-3-mediated nuclear export after Foxo phosphorylation by phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB, Akt) or other cellular kinases like IkB kinase (IKK) b (Hu et al., 2004) , serum/glucocorticoid-regulated kinase (Brunet et al., 2001; You et al., 2004) , casein kinase 1 (Rena et al., 2002 (Rena et al., , 2004 , dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (Woods et al., 2001) , cyclin-dependent kinase 2 (Huang et al., 2006) and mammalian Ste20-like kinase (Lehtinen et al., 2006) . Some phosphorylation events, however, can regulate Foxo activity independent of nuclear shuttling-for example, phosphorylation mediated by Ras-related GTPase (Ral) -Jun kinase and other mitogen-activated protein kinase pathways (De Ruiter et al., 2001; Essers et al., 2004; Asada et al., 2007) . In addition, other posttranslational modifications may modulate Foxo activity: acetylation by cAMP response element-binding protein -binding protein (CBP)/p300 at the lysine residue of the forkhead domain, for instance, reduces transcriptional activity but also sensitizes Foxo for phosphorylation by PKB, in contrast to deacetylation by silent information regulator 2 (Brunet et al., 2004; Daitoku et al., 2004; Motta et al., 2004; van der Horst et al., 2004; Matsuzaki et al., 2005; Nakae et al., 2006) . Also, ubiquitination, as regulated by ubiquitin ligases like Skp2 and deubiquitinases like USP7, further modulates Foxo proteins by promoting proteosomal degradation and/or inhibition of transcriptional activity (Matsuzaki et al., 2003; Plas and Thompson, 2003; Huang et al., 2005; van der Horst et al., 2006) . The regulation of Foxo proteins therefore reflects a complex network of biochemical interactions, with heavy post-translational regulation during cellular signaling.
Beyond simply traditional transactivation by target gene binding and direct interactions with basic transcriptional machinery (for example, So and Cleary, 2003) , Foxo proteins regulate target gene transcription by a diverse array of mechanisms. For instance, Foxo proteins may cooperate with one of many cofactors, including CBP/p300, to promote histone acetylation (reviewed in refs. van der Heide and Smidt, 2005; Wijchers et al., 2006) . Other known coactivators, corepressors and/or interacting proteins include Smad, STAT, PPAR, Runx, p53 and other Fox family members as well as nuclear androgen, glucocorticoid, thyroid and retinoic acid receptors (reviewed in refs. Coffer and Burgering, 2004; Wijchers et al., 2006; Yamamura et al., 2006; You et al., 2006b) . Indeed, surprisingly, many target gene effects by Foxo have been shown to be independent of the DNA-binding domain, suggesting that many Foxo functions reflect largely protein-protein interactions (Ramaswamy et al., 2002) .
Foxo target genes are involved in cell cycle, proliferation, survival and apoptosis, and include the cell cycle inhibitors p27 Kip1 , p21
Cip1
, retinoblastoma family member p130, cyclins B1 and G2 and the checkpoint protein growth arrest and DNA damage-inducible protein (GADD) 45a; the pro-apoptotic factors Bim and Fas ligand (CD95L) (reviewed in refs. Lam et al., 2006; Wijchers et al., 2006) ; as well as differentiation factors such as Id1 (Birkenkamp et al., 2007) . Foxo proteins also protect cells from oxidative stress via the induction of target genes like superoxide dismutase (SOD) 2 (Mn-SOD) and catalase Nemoto and Finkel, 2002) . Through the control of such critical target genes in multiple biological systems, Foxo proteins play critical roles in organismal homeostasis.
Immunology of the Foxo transcription factors

Foxo proteins in T cells
Although most immunological roles for the Foxo's have been inferred from the aforementioned non-immunological systems and/or Foxo-related pathways, such as studies of PI3K and PKB pathway in rheumatoid arthritis and T cells (Fabre et al., 2006; Reedquist et al., 2006) , several recent studies have begun to elucidate the roles of the individual Foxo's in immunity (summarized in Table 1 and Figure 1 ). In T cells, Foxo proteins seem largely regulated by T cell receptor (TCR) and/or CD28 ligation-induced signals, and/or IL-2, explained largely by PI3K/PKB activation: in IL-2-dependent mouse CTLL-2 T cells, IL-2 withdrawal results in the dephosphorylation of Foxo3a and Foxo4, associated with the induction of the Foxo target genes Bim and p27
Kip1
-a process mimicked by a constitutively active Foxo1 (T24A/S256A/S319A; '3A mutant') (Stahl et al., 2002) . In the human leukemia T cell line Jurkat, overexpression of Foxo1 suppresses proliferation (Medema et al., 2000) , while overexpression of Foxo3a induces apoptosis (Brunet et al., 1999) , while in primary human T cells, TCR ligation recruits p85a PI3K to the immune synapse, and the subsequent tyrosine kinase activity correlates with nuclear exclusion and phosphorylation of Foxo1 (Stahl et al., 2002; Fabre et al., 2005) . Nucleofection of the 3A mutant Foxo1 impairs human T cell growth and/or proliferation, but not early activation as judged by CD69 expression (Fabre et al., 2005) . In addition, CTLA4 ligation can conversely protect activated T cells from apoptosis, including activation-induced cell death, correlating with Foxo3a phosphorylation and diminished CD95L expression (Pandiyan et al., 2004) . Interestingly, CD95/CD95L-induced expression of Bim via Foxo3a may indirectly reflect the induction of H 2 O 2 by CD95 signaling, indicating an intersection of the apoptotic and oxidative stress functionalities (Bosque et al., 2007) .
TCR-mediated regulation of Foxo proteins is now known to involve at least the Vav family of guanine exchange factors for Rho GTPases: Vav1-and Vav1/ 3-deficient T cells exhibit impaired phosphorylation and 14-3-3 association of Foxo1, as well as impaired p27
Kip1 downregulation, in response to TCR ligation. In contrast, Vav1-deficient T cells demonstrate normal IL-2-induced Foxo1 phosphorylation and p27 Kip1 downregulation-suggesting that Vav1 promotes a TCR-specific pathway of T cell cycle progression and proliferation by enabling the inhibition of Foxo1, presumably via the PI3K/PKB pathway (Charvet et al., 2006) . Overall, Foxo proteins mediate cytokine withdrawal and/or mitogen absence-induced apoptosis by inducing known pro-apoptotic and/or cell cycle cessation target genes, like Bim and p27
. Nonetheless, growing evidence indicates that Foxo proteins likely utilize multiple, still unidentified target genes as well: for instance, microarray studies involving an inducible Foxo3a construct in p53-deficient murine embryonic fibroblast cells have identified the pro-apoptotic Bcl-2 homolog Puma as a Foxo3a target gene: IL-2 withdrawal in T cells resulted in the upregulation of Puma and Bim, associated with dephosphorylation of Foxo3a, increased occupancy of Foxo3a on the Puma and Bim promoters, and cellular apoptosis. Knockdown of Foxo3a by shRNA prevented Puma induction in serum-starved murine embryonic fibroblasts bearing a transcriptionally inactive form of p53 (L25Q, W26S, A135 V) (You et al., 2006a) . At the same time, though, even additional Foxo-dependent pathways appear to modulate overall cellular effects; the recently described Foxo3a target glucocorticoid-induced leucine zipper transiently protects CTLL-2 T cells from IL-2 withdrawal-induced apoptosis (Asselin-Labat et al., 2004) . Thus, multiple additional Foxo target genes likely mediate a number of feedback loops, which regulate cellular homeostasis.
Functionally, though, the importance of the Foxo proteins in T cells has only been definitively demonstrated and reported so far for Foxo3a, where Foxo3a deficiency in mice leads to spontaneous, autoreactive helper T cell activation, Th1 and Th2 cytokine production and a mild lymphoproliferative, autoimmune syndrome that includes inflammatory lesions in multiple end organs. Interestingly, these findings appear independent of an apoptosis phenotype, because Foxo3a-deficient T cells seemed to perform normally in assays of activation-induced cell death, among others. Instead, Foxo3a-deficient T cells possessed unrestrained NF-kB activation, correlated with diminished levels of inhibitor of NF-kB proteins. Foxo3a therefore likely acts as a T cell quiescence, tolerance and/or suppressive factor by upregulating the inhibitory components of the NF-kB pathway .
Such observations imply disease relevance in systemic autoimmunity: in the 16/6 idiotype anti-DNA idiotype experimentally-induced model of systemic lupus erythematosus in BALB/c mice, treatment with a peptide based on the complimentarity determining region 1 of the idiotype ameliorates several clinical parameters of disease, including autoantibody titers and kidney disease, associated with diminished IFN-g expression and, among other findings, increased expression in T cells of Foxo3a. This appears to be due to the induction of the immunoregulatory cytokine TGF-b, since T cells from hCDR1-treated animals expressed increased TGF-b, and antibody-mediated neutralization of TGF-b abrogated the hCDR1-induced upregulation of Foxo3a, at least in vitro (Sela et al., 2006) .
Other T cell subpopulations, however, likely also involve regulation of Foxo3a for their homeostasis. Human central memory T cells, for instance, possess increased resistance to spontaneous and CD95-induced apoptosis than effector memory T cells, increased levels of phosphorylated Foxo3a and diminished quantities of several Foxo3a target genes as judged by microarray analysis, such as the proapoptotic target Bim. Pharmacological inhibition of the Foxo3a kinases IKK and PKB in vitro rendered human central memory T cells more susceptible to apoptosis, mimicking effector memory T cells. These findings suggest that human central memory T cell survival is driven by Foxo3a inactivation, which presumably results from the convergence of TCR and cytokine signaling (Riou et al., 2007) .
A converse role for Foxo3a may participate in human regulatory T cells, which exhibit impaired PKB phosphorylation in association with reduced levels of phosphorylated Foxo1 and Foxo3a. Interestingly, enforced expression of an activated (PH domain-deficient) (Crossley, 2003) Abbreviations: CA, constitutively-active mutant; DC, dendritic cell; fMLP, formyl-Met-Leu-Phe; GILZ, glucocorticoid-induced leucine zipper; PMN, polymorphonuclear neutrophil; Rb, retinoblastoma protein; SOD, superoxide dismutase. 'Correlation' indicates an indirect demonstration of the Foxo's involvement, e.g., a correlation between Foxo phosphorylation and p27 Kip1 expression in Vav-deficient T cells (Charvet et al., 2006) . Adapted from (Peng, 2007) . PKB isoform, which presumably would increase phosphorylated Foxo species, partially reversed the suppressive capacity of regulatory T cells in vitro, associated with restoration of their ability to produce several cytokines such as IFN-g, but not IL-2, without affecting expression levels of Foxp3, CTLA4, CD25, or granzymes A/B (Crellin et al., 2007) . Foxo proteins therefore play diverse roles in multiple T cell subsets (Table 1) .
Foxo proteins in B cells
Analogous pathways likely regulate Foxo proteins in B cells, although emerging data clearly indicate specific differences (Table 1) . Overexpression of Foxo3a in the mouse pre-B cell line Ba/F3 can also induce apoptosis and in mouse primary B cells, BCR cross-linking induces nuclear exportation of Foxo1 in a manner that can be inhibited by the PI3K inhibitor LY294002 (Yusuf et al., 2004) . Retroviral transduction of A3 mutant versions of Foxo1 or Foxo3a into activated primary mouse B cells resulted in a modest cell cycle arrest and annexin V positivity, suggesting that optimal B cell proliferation requires inactivation of the Foxo proteins. This cell cycle arrest appears to reflect cooperation of Foxo proteins with the transcription factor dEF1 to induce the expression of the cell-cycle arrest genes cyclin G2 and retinoblastoma p130, as demonstrated by in vitro studies involving ectopic expression . Here, B cell regulation of Foxo activity does not appear to be limited to posttranslational phosphorylation: BCR crosslinking also suppresses Foxo1 mRNA expression in a PI3K-and Btk-dependent manner, whereas the induction of phosphorylated Foxo1 is Btk-independent, at least at Ser256 and at least in mouse B cells. Foxo3a and Foxo4 mRNAs are also suppressed by BCR ligation (Hinman et al., 2007) . Finally, in v-Abl-transformed pre-B cells from bcl-2 transgenic SCID mice, temperature-sensitive inactivation of v-Abl results in cell cycle arrest and an increased nuclear abundance of Foxo3a and p27. Reactivation reinitiates cell cycle entry, associated with diminished Foxo3a and p27. Interestingly, this reactivation is associated with attenuated NF-kB activity, suggesting that the NF-kB-inhibiting function of Foxo3a may not play a critical physiological role, at least in this system (Jacobsen et al., 2006) . Thus, B cells may utilize both translational and post-translational mechanisms to modulate Foxo activity, which, as in T cells, also regulates cell survival and proliferation, but perhaps via less of an effect on the NF-kB pathway.
Foxo proteins in non-lymphoid lineages
Nonetheless, many Foxo pathways appear to be analogous across multiple immune-relevant cell lineages. , leading eventually to proteosomal degradation. In the absence of such inhibitory processes, Foxo proteins shuttle into the nucleus, where they transactivate target genes, which mediate multiple cellular processes, including cell cycle arrest, apoptosis, quiescence and immune tolerance. Note that many aspects of this model have been derived from studies in non-immunological systems, and have been extrapolated to lymphocytes here. Adapted from (Peng, 2007) .
For instance, in the hematopoietic cell lines MC/9, FDC-P1 and TF-1, cytokine withdrawal results in increased CD95L, Bim and p27 expression, correlating with Foxo3a phosphorylation (Behzad et al., 2007) . Also, animals bearing combined deficiencies in Foxo1, Foxo3a and Foxo4 (Foxo-deficient) develop deficiencies in hematopoietic stem cells due to an impaired resistance to oxidative stress (Tothova et al., 2007) , indicating that Foxo proteins play key roles in the regulation of stem cell differentiation and development.
In non-obese diabetic mice, the tolerogenic potential of IFN-g is lost in CD8 þ dendritic cells, apparently due to peroxynitrite-mediated nitration of STAT1 which impairs the IFN-g signaling pathway. Treatment of non-obese diabetic dendritic cells with CTLA4-Ig in vitro confers tolerogenic properties due to increased Foxo3a activity, as judged by siRNA and luciferase reporter assays-which results in increased superoxide dismutase 2 (Mn-superoxide dismutase) expression, and an improvement in IFN-g-dependent tryptophan catabolism. This pathway likely involves CTLA4-Iginduced activation of phosphatase and tensin homolog and inactivation of PKB, through which the increased superoxide dismutase 2 activity diminishes peroxynitrite formation which in turn relaxes the STAT1 impairment (Fallarino et al., 2004) . Modulation of Foxo pathways in dendritic cells therefore may possess therapeutic value in a variety of inflammatory diseases.
In poylmorphonuclear neutrophils, Foxo proteins appear to play critical roles in the regulation of cellular survival. In human poylmorphonuclear neutrophils, exposure to the bacterially derived chemoattractant formyl-Met-Leu-Phe results in phosphorylation of Foxo1, Foxo3a and Foxo4, apparently via PI3K and mitogen-activated protein kinase -dependent pathways as judged by pharmacological inhibitors in vitro (Crossley, 2003) . Interestingly, formyl-Met-Leu-Phe also induces the Bcl-2-related survival factor Mcl-1, which is capable of forming a complex with Foxo1 and may therefore coordinate neutrophil survival via modulation of Foxo activity. However, it is interesting to note that PI3Kg-deficient neutrophils have only modestly diminished levels of phospho-Foxo1, implying redundancy among the PI3K isoforms in activating PKB to inactivate Foxo proteins and/or perhaps the presence of non-PI3K pathways to Foxo inactivation in neutrophils (Yang et al., 2003) .
Nonetheless, at least Foxo3a clearly plays critical roles in neutrophil survival, as demonstrated by Foxo3a-deficient mice which are resistant to both thioglycollate-induced peritonitis and the passive K/B Â N serum transfer model of arthritis, two neutrophilic models of inflammation . Foxo3a-deficient neutrophils appear to enter target organs, but undergo apoptosis due to an inability to suppress the upregulation of CD95L. Thus, Foxo3a is required to prevent inflammationinduced apoptosis of neutrophils via CD95L, surprisingly demonstrating an anti-apoptotic function for Foxo3a via its ability to suppress CD95L expression.
Interestingly, a Foxo3a haplotype has recently been reported to associate with erosive activity in adult rheumatoid arthritis (Hughes et al., 2006) , where cell lineage-specific inactivation of Foxo family members has also been observed in synovial fibroblastlike synoviocytes, T cells and macrophages (Ludikhuize et al., 2007) . Such findings suggest that Foxo3a may be a key target for therapeutic modulation in rheumatoid and/or perhaps other inflammatory arthritides.
Potential considerations for Foxo proteins in inflammatory diseases
It is tempting to speculate upon the utility of Foxo proteins as targets of therapeutic intervention in inflammatory diseases, since they appear to play such key roles in cells relevant to inflammatory disease pathogenesis. Blockade of Foxo, or at least of Foxo3a, activity in inflammatory arthritis, for instance, may be of particular interest, but on the other hand, amplification of Foxo activity may be desired in diseases such as systemic lupus erythematosus or type 1 diabetes. For optimal disease positioning, continued studies would be required to explore both the breadth of diseases in which Foxo family members participate, as well as the relative context-dependent roles of the various individual Foxo family members.
At the same time, chemical tractability of the Foxo proteins for the generation of agonist or antagonist molecules is and will likely remain a developmental issue, since non-ligand transcription factors in general remain highly challenging targets for small molecule intervention due to their large biologically-relevant interfaces (reviewed in Aud and Peng, 2006) . Recent success with other transcription factor families, such as AP-1, however, offer hope for the development of small molecular modulators of Foxo activity (Tsuchida et al., 2006) . Theoretically, other strategies successfully used to target other transcription factors, such as decoy oligonucleotides or short interfering RNA molecules, may be successful here, but these interventions would be limited by the current pharmacokinetic limitations of such molecules in vivo, and also would be restricted to Foxo antagonism. On the other hand, intervention upon other, more chemically tractable targets within the Foxo pathway may hold promise, as suggested by studies with inhibitors of CK1 or PI3K (Rena et al., 2004; Yau et al., 2005) , and library screens which have yielded phosphorylation-dependent inhibitors of Foxo nuclear export (Kau et al., 2003; Georgiades and Clardy, 2005; Schroeder et al., 2005) . Challenges of substrate specificity will likely pervade, since multiple Fox proteins, both Foxo and non-Foxo, likely share multiple up-and down-stream pathway regulators, yet the diverse functions of Fox family members in the immune system suggests that high target specificity will be required for clinical success (reviewed in refs. Coffer and Burgering, 2004; .
Conclusions
Emerging data indicate that Foxo proteins play key roles in the regulation of inflammation, but significant knowledge gaps remain; whereas Foxo3a modulates helper T cell quiescence and inflammatory neutrophil survival, the specific roles of the other Foxo proteins, and the roles of Foxo3a in other cell lineages, remains still incompletely understood. Importantly, many current models of Foxo functions in the immune system have been extrapolated from more fundamental biological systems, such as cancer or metabolism and it remains unclear how frequently parallels may be drawn (Figure 1 ). Nonetheless it is intriguing to consider the possibility that Foxo proteins, by virtue of their roles in diverse biological processes, mediate molecularly the intersection and impact of non-immune biological systems and the immune system-for example, given the importance of Foxo in metabolism of glucose and other endocrine systems, it is tempting to envision Foxo as a key point of intersection for endocrine-immune interactions (Zhuang et al., 2006) . Still, as is the case for Foxo3a and neutrophils, extrapolation from transformed cell line data can be misleading, since Foxo proteins can promote apoptosis via CD95/CD95L in some cellular systems, but in vivo Foxo3a in fact protects against apoptosis via CD95/ CD95L in primary cells-thus Foxo proteins may likely either enhance or repress the transcription of target genes, perhaps through the recruitment of gene-specific coactivators or corepressors . Furthermore, the relative importance of additional pathways beyond mitogen-induced PI3K pathways will require additional study: for instance, the ability of the C5b-9 complement complex to regulate Foxo activity in correlation with proliferation, at least in some cell types (Fosbrink et al., 2006) , suggests that tissue-and/or context-specific pathways and functions exist for the Foxo proteins, requiring significant future studies for complete elucidation. Continued evaluation on the Foxo proteins in immunity, correlated with their involvement in other biological systems, will therefore hopefully elucidate disease-relevant, tissue-specific pathways, bearing insight into disease pathogenesis and/or therapies.
